GlassScriptPhysician profile
Todd Warner Gandy
NPI 1467898767
$10,431.84
in general payments reported to CMS, 2019-2025
33 companies · $3,011 in 2025
The $3,011 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $312 · 2021: $1,175 · 2022: $1,304 · 2023: $1,723 · 2024: $2,805 · 2025: $3,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,538.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,658.75 | 2020-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $1,371.30 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $932.83 | 2021-2025 | Dupixent |
| Genzyme Corporation | $794.71 | 2022-2025 | |
| United Therapeutics Corporation | $738.42 | 2024-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $698.09 | 2020-2025 | Arikayce |
| Electromed, INC. | $550.31 | 2021-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $467.66 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $423.24 | 2023-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.92 | 2020-2025 | Ofev, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $322.46 | 2022-2025 | Zerbaxa, Winrevair, Recarbrio |
| Baxter Healthcare | $218.70 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $174.81 | 2024-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $160.71 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Verona Pharma, INC. | $159.98 | 2025 | Ohtuvayre |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $150.00 | 2022 | |
| Advanced Respiratory, INC | $143.72 | 2021 | |
| Amgen INC. | $142.81 | 2022-2025 | Tezspire |
| Pulmonx Corporation | $142.78 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mylan Specialty L.P. | $128.25 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $110.95 | 2022-2024 | |
| Genentech USA, INC. | $93.54 | 2021-2023 | Xolair |
| Grifols USA, LLC | $69.20 | 2021-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $66.83 | 2025 | Yupelri |
| Vifor Pharma, INC. | $56.96 | 2025 | Zemaira |
| Astellas Pharma US INC | $55.08 | 2023-2024 | Cresemba |
| La Jolla Pharmaceutical Company | $53.81 | 2021-2025 | Giapreza |
| Bard Peripheral Vascular, INC. | $38.49 | 2021-2022 | |
| Abbvie INC. | $37.08 | 2023-2024 | |
| Shionogi INC | $26.52 | 2024 | Fetroja |
| Arbor Pharmaceuticals, INC. | $21.11 | 2021 | |
| Beckman Coulter, INC. | $16.78 | 2025 | Access 2 |
| Teva Pharmaceuticals USA, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Gandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.